
ROCHE HOLDING AG-BR and partner ELI LILLY & CO secured United States regulatory clearance for an Alzheimer's blood test. The Elecsys pTau217 biomarker test targets patients aged 55 and older with cognitive decline.
The FDA has cleared Roche and Eli Lilly to market a new blood test designed to help detect signs of Alzheimer disease in older adults experiencing cognitive decline. The biomarker test offers a less invasive alternative to traditional PET scans and spinal fluid tests.

ROCHE HOLDING AG-BR and partner ELI LILLY & CO secured United States regulatory clearance for an Alzheimer's blood test. The Elecsys pTau217 biomarker test targets patients aged 55 and older with cognitive decline.
Everything you use on the web — faster, and in your pocket.